Bruker Corporation

Report azionario NasdaqGS:BRKR

Capitalizzazione di mercato: US$6.7b

Bruker Crescita futura

Criteri Future verificati 3/6

Bruker prevede che gli utili e i ricavi cresceranno rispettivamente di 103% e 4.6% all'anno. Si prevede che l'EPS crescerà di 103.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 14.4% in 3 anni.

Informazioni chiave

103.0%

Tasso di crescita degli utili

103.09%

Tasso di crescita dell'EPS

Life Sciences crescita degli utili17.5%
Tasso di crescita dei ricavi4.6%
Rendimento futuro del capitale proprio14.43%
Copertura analitica

Good

Ultimo aggiornamento09 May 2026

Aggiornamenti recenti sulla crescita futura

Articolo di analisi • Feb 15

Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report

It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...

Recent updates

Aggiornamento dell'analisi • Apr 29

BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path

Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.
Aggiornamento dell'analisi • Apr 15

BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings

Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.
Aggiornamento dell'analisi • Apr 01

BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E

Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.
Seeking Alpha • Mar 31

Bruker: A Better, Yet Speculative Proposition

Summary Bruker's shares have declined 40% since January, pressured by weak 2025 results and a cautious 2026 outlook. 2025 saw organic sales decline 4%, high leverage (~3x), and significant M&A activity, raising concerns about capital allocation. 2026 guidance calls for modest 4–5% sales growth, 1–2% organic, and adjusted EPS of $2.10–$2.15, lowering valuation to 15–16x earnings. While conviction remains low due to uneven execution, the risk-reward is improving, warranting consideration of a small speculative position on further dips. Read the full article on Seeking Alpha
Aggiornamento dell'analisi • Mar 18

BRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E

Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.
Aggiornamento dell'analisi • Mar 03

BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E

Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.
Aggiornamento dell'analisi • Feb 17

BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions

Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.
Articolo di analisi • Feb 15

Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report

It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...
Aggiornamento dell'analisi • Feb 03

BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple

Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.
Aggiornamento dell'analisi • Jan 20

BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple

Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.
Aggiornamento dell'analisi • Jan 06

BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations

Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.
Aggiornamento dell'analisi • Dec 17

BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations

Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.
Aggiornamento dell'analisi • Dec 03

BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations

Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.
Articolo di analisi • Nov 26

Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry

Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...
Aggiornamento dell'analisi • Nov 19

BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook

Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.
Aggiornamento dell'analisi • Nov 03

BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience

Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.
Articolo di analisi • Aug 10

Why Investors Shouldn't Be Surprised By Bruker Corporation's (NASDAQ:BRKR) 31% Share Price Plunge

NasdaqGS:BRKR 1 Year Share Price vs Fair Value Explore Bruker's Fair Values from the Community and select yours The...
Aggiornamento dell'analisi • Aug 06

Renewed Biopharma Funding And Cost Savings Will Revitalize Markets

Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).
Articolo di analisi • Jun 25

Revenues Working Against Bruker Corporation's (NASDAQ:BRKR) Share Price

Bruker Corporation's ( NASDAQ:BRKR ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now...
Articolo di analisi • May 31

A Look At The Fair Value Of Bruker Corporation (NASDAQ:BRKR)

Key Insights The projected fair value for Bruker is US$43.42 based on 2 Stage Free Cash Flow to Equity Bruker's...
Articolo di analisi • May 16

Bruker's (NASDAQ:BRKR) Soft Earnings Don't Show The Whole Picture

The market for Bruker Corporation's ( NASDAQ:BRKR ) shares didn't move much after it posted weak earnings recently. We...

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:BRKR - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20283,950N/A3064097
12/31/20273,74416127435012
12/31/20263,58812027235312
3/31/20263,459-3622140N/A
12/31/20253,437-2214134N/A
9/30/20253,439-24-1194N/A
6/30/20253,4438049166N/A
3/31/20253,44680175295N/A
12/31/20243,366113136251N/A
9/30/20243,241305157267N/A
6/30/20243,120352168273N/A
3/31/20243,001402181284N/A
12/31/20232,965427243350N/A
9/30/20232,818319206316N/A
6/30/20232,715319201342N/A
3/31/20232,621312149284N/A
12/31/20222,531297145274N/A
9/30/20222,506275119242N/A
6/30/20222,476274114196N/A
3/31/20222,458282176262N/A
12/31/20212,418277190282N/A
9/30/20212,362270254347N/A
6/30/20212,264238312405N/A
3/31/20212,118204304395N/A
12/31/20201,988158235332N/A
9/30/20201,960158169265N/A
6/30/20201,970165140235N/A
3/31/20202,035177141234N/A
12/31/20192,073197N/A213N/A
9/30/20192,026207N/A210N/A
6/30/20191,972189N/A185N/A
3/31/20191,925184N/A210N/A
12/31/20181,896180N/A240N/A
9/30/20181,87398N/A211N/A
6/30/20181,84292N/A219N/A
3/31/20181,81384N/A166N/A
12/31/20171,76679N/A154N/A
9/30/20171,706151N/A142N/A
6/30/20171,664161N/A142N/A
3/31/20171,621152N/A177N/A
12/31/20161,611154N/A131N/A
9/30/20161,619146N/A190N/A
6/30/20161,621111N/A208N/A
3/31/20161,646119N/A188N/A
12/31/20151,624102N/A229N/A
9/30/20151,65466N/A149N/A
6/30/20151,67760N/A108N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che BRKR diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che BRKR diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede BRKR diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di BRKR ( 4.6% all'anno) crescerà più lentamente rispetto al mercato US ( 11.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di BRKR ( 4.6% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di BRKR sarà basso tra 3 anni ( 14.4 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/11 02:10
Prezzo dell'azione a fine giornata2026/05/11 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Bruker Corporation è coperta da 29 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Luke SergottBarclays
Michael RyskinBofA Global Research
Paul KnightBrean Capital Historical (Janney Montgomery)